scholarly journals Control of T lymphocyte fate decisions by PI3K signaling

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 1171
Author(s):  
Benjamin Murter ◽  
Lawrence P. Kane

Virtually all aspects of T and B lymphocyte development, homeostasis, activation, and effector function are impacted by the interaction of their clonally distributed antigen receptors with antigens encountered in their respective environments. Antigen receptors mediate their effects by modulating intracellular signaling pathways that ultimately impinge on the cytoskeleton, bioenergetic pathways, transcription, and translation. Although these signaling pathways are rather well described at this point, especially those steps that are most receptor-proximal, how such pathways contribute to more quantitative aspects of lymphocyte function is still being elucidated. One of the signaling pathways that appears to be involved in this “tuning” process is controlled by the lipid kinase PI3K. Here we review recent key findings regarding both the triggering/enhancement of PI3K signals (via BCAP and ICOS) as well as their regulation (via PIK3IP1 and PHLPP) and how these signals integrate and determine cellular processes. Lymphocytes display tremendous functional plasticity, adjusting their metabolism and gene expression programs to specific conditions depending on their tissue of residence and the nature of the infectious threat to which they are responding. We give an overview of recent findings that have contributed to this model, with a focus on T cells, including what has been learned from patients with gain-of-function mutations in PI3K as well as lessons from cancer immunotherapy approaches.

2005 ◽  
Vol 184 (1) ◽  
pp. 320-341 ◽  
Author(s):  
Yanan Zheng ◽  
Venkataramanan Balakrishnan ◽  
Greg Buzzard ◽  
Robert Geahlen ◽  
Marietta Harrison ◽  
...  

Author(s):  
Justyna Hermanowicz ◽  
Beata Sieklucka ◽  
Krzysztof Nosek ◽  
Dariusz Pawlak

One of the main mechanisms for avoiding immune response by cancer cells is by inducing an immunosuppressive environment in the tumor, following the activation of immune checkpoints i.e. PD-1 or CTLA-4  receptor inhibitors on T lymphocytes. Inhibiting the interaction between PD-1 or CTLA-4 and their ligands (PD-L1, CD80, and CD85) leads to unblocking T-lymphocyte function, and thus destroying cancer cells. Certain intracellular signaling pathways are also involved in the development of tumor cell immunoresistance. Blocking the activation of immunosuppressive pathways  may increase immunological anti-tumor control


2012 ◽  
Vol 11 (11) ◽  
pp. 795-798 ◽  
Author(s):  
Rizgar A. Mageed ◽  
Soizic Garaud ◽  
Taher E. Taher ◽  
Kaushal Parikh ◽  
Jacques-Olivier Pers ◽  
...  

1994 ◽  
Vol 269 (18) ◽  
pp. 13162-13166
Author(s):  
Y. Konda ◽  
I. Gantz ◽  
J. DelValle ◽  
Y. Shimoto ◽  
H. Miwa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document